← board
AGTX
distress 4/10 · elevated risk$0.020%today-60% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
0%
Price & events
-59.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+17.6%
1M
-54.4%
3M
-59.9%
6M
-22.3%
1Y
-23.4%
2Y
-97.5%
5Y
-96.0%
All
Overview
- Market Cap
- $801.34K
- Volume
- 0
- 52 Week Range
- $0.02 – $0.05
- Total Shares
- 40.07M
- % Held by Insiders
- 20.91%
- % Held by Institutions
- 0.00%
- Beta
- 0.71
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 40,066,951 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.